Physician profile
Christopher David Anna
NPI 1144262148
$2,829.70
in general payments reported to CMS, 2019-2025
41 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $362 · 2021: $560 · 2022: $637 · 2023: $432 · 2024: $232 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $459.23 | 2019-2022 | |
| Smith+Nephew, INC. | $371.02 | 2019-2025 | Vlp Foot, Collagenase Santyl, Grafix Pl |
| Ibsa Pharma INC. | $269.31 | 2021-2024 | Tirosint, Licart, Tirosint |
| Melinta Therapeutics, LLC | $238.84 | 2021-2022 | |
| Bioventus LLC | $168.78 | 2020-2024 | Exogen Ultrasound Bone Healing System |
| Nevro Corp. | $108.79 | 2021-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Organogenesis INC. | $84.83 | 2021-2023 | Puraply |
| Abbvie INC. | $75.41 | 2021-2023 | Dalvance |
| Extremity Medical | $70.33 | 2019 | |
| Stryker Corporation | $68.01 | 2021-2025 | Alphavent |
| Fidia Pharma USA INC. | $64.76 | 2023 | Triluron, Hymovis |
| Paratek Pharmaceuticals, INC. | $57.67 | 2024-2025 | Nuzyra |
| Depuy Synthes Sales INC. | $57.04 | 2021-2023 | Na, N/A, Motoband |
| Nabriva Therapeutics, Plc | $55.88 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Anna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.